


INVESTMENT MANAGEMENT PHILOSOPHY

The TFCM Aspire Strategy adheres to the same disciplined process that is applied to our flagship Core Growth Strategy, which has been deployed by the principals of Taylor Frigon for almost three decades. Over that period of time, an integral part of our investment strategy has been to invest in companies possessing unique characteristics of solid core growth companies, primarily in the areas of core technology, healthcare and biotechnology. The TFCM Aspire strategy portfolio is a derivative of the TFCM Core Growth Strategy and is made up of what the Investment Committee determines to be the companies with the highest growth potential. As such, the TFCM Aspire Strategy is a highly concentrated portfolio and will generally consist of ten to fifteen companies, therefore, it is a highly aggressive strategy.

TFCM Aspire Strategy

We have been heavily researching and investing in high growth companies in core technology, healthcare and biotechnology for decades at TFCM. Our experience in our venture capital partnership, Taylor Frigon Capital Partners LP, uniquely exposes us to some of the most exciting aspects of these markets and provides us the insight and knowledge necessary to navigate the complex concepts that exist in the most innovative and rapidly changing industries of today. The most significant scientific and technological advances are happening in only a few industries and the TFCM Aspire Strategy is well-positioned for the investor that desires exposure to these significant growth opportunities.



	Total Return		Annualized TR		Cumulative
	QTD	YTD	1 YEAR	since inception ¹	since inception ¹
TFCM Net	11.14%	34.32%	48.76%	32.54%	63.75%
TFCM Gross	11.47%	35.59%	50.65%	34.24%	67.45%
NASDAQ	5.79%	20.67%	22.29%	16.03%	29.73%
S & P 500	4.48%	14.24%	18.61%	15.09%	27.90%
Russell 2500	4.74%	11.00%	17.80%	30.53%	30.53%

¹ Inception date 12/31/2015

Please refer to back page for full GIPS® presentation.

Aspire Strategy Selection Process

The TFCM Aspire Strategy uses the same time-tested growth selection process as our Core Growth Strategy, but focused specifically on a subset of the fastest growing companies we can find. We are not stock traders, we buy businesses we want to own for years.

Our efforts and expertise are focused on identifying promising high growth companies, primarily in core technology, medical technology and biosciences: companies whose creative strategic vision can provide maximum potential for significant long-term capital appreciation.

Using the same traditional fundamental analysis and qualitative metrics as the Core Growth Strategy, we assess a company's vision and market position; evaluate its prospects for revenue, earnings growth and margin expansion; and compare its attributes to others in its industry and specific vertical within the broader technology sector, across the globe.

We analyze management's ability to adapt to shifting market conditions and evaluate how their vision for their products and/or services aligns with our own thesis. We determine whether management instills tight internal controls, meets or exceeds expectations and we assess how the company will benefit from global macro trends and themes. Our objective is to purchase outstanding, high-growth businesses and own them for many years until their value is fully realized.

The Aspire Strategy benefits greatly from our exposure to venture capital as we discover new innovations and technologies.





Top 5 Holdings By Weighting	Mkt. Cap (\$Mil)
QuickLogic	135
Mellanox	2,372
Silicom	427
Tower Semiconductor	2,860
Arista Networks	13,747
Portfolio Avg	3,908

Industry/ Sector Representation	
Data Center Networking	AI/VR/AR/GPUs
IT Consulting Services	FPGAs
Automotive Technology	Data Center Connectivity
Network Processors	Semiconductor Fabrication
Genetic Testing	

GIPS® compliance indicates that a firm adheres to the overall guiding principles of the GIPS® standards: fair representation and full disclosure of a firm's investment performance. Participation in GIPS® is voluntary and regulators do not require investment management firms to follow it, signifying that those firms who undergo this process are truly committed to reporting and performance excellence.

ANNUAL PERFORMANCE RESULTS															
Year End	Total Firm Assets (millions)	Composite Assets			NASDAQ	NASDAQ		S&P 500	S&P 500		Russell 2500	TFCM Aspire Composite			Composite Dispersion
		USD (millions)	# of Accts	Non-fee Paying Accts		3 Yr Std Dev	S&P 500		3 Yr Std Dev	Gross		3 yr Gross Std Dev	Net		
														2017 YTD#	
2017 YTD#	\$148.167	\$2.245	34	3.01%	20.67%	NA	14.24%	NA	11.00%	NA	35.59%	NA	34.32%	NA	
2016	\$128.752	\$1.128	31	4.34%	7.50%	NA	11.96%	NA	17.60%	NA	23.50%	NA	21.91%	4%	

NA - Information is not presented due to an insufficient number of portfolios in the composite period. In addition, the three-year annualized ex-post standard deviation of the composite and the benchmark are not presented because 36 monthly returns of the composite are not available.

Preliminary pending examination by ACA Performance Services LLC

Aspire Composite contains fully discretionary Aspire Strategy accounts which invest primarily in 10-20 growth stocks in the areas of core technology, health care and biotechnology, with small components of cash, and for comparison purposes is measured against the NASDAQ, S&P 500 and Russell 2500 indices. In March 2017, upon review of indices used for comparison in TFCM composites, it was determined that the Russell 2500 would be a more adequate index than the Russell 3000. Subsequently, we have retroactively to inception changed from using the Russell 3000 to the Russell 2500 as comparison index for this composite. The Russell 2500 Index measures the performance of the small to mid-cap segment of the U.S. equity market. The Russell 2500 Index includes 2500 of the smallest securities based on a combination of their market cap and current index membership.

The Aspire Composite was created 12/31/2015.

Taylor Frigon Capital Management, LLC (TFCM) claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. TFCM has been independently verified for the periods 01/19/2007 through 12/31/2015 by Ashland Partners LP, and for 01/01/2016 to 12/31/2016 by ACA Performance Services LLC. The verification report is available upon request. Verification assesses whether (1) the firm has complied with all the composite construction requirements of the GIPS standards on a firm-wide basis and (2) the firm's policies and procedures are designed to calculate and present performance in compliance with GIPS standards. Verification does not ensure the accuracy of any specific composite presentation.

TFCM is an independent registered investment adviser. The firm's list of composite descriptions is available upon request. Results are based on fully discretionary accounts under management, including those accounts no longer with the firm and past performance is not indicative of future results.

The U.S. Dollar is the currency used to express performance. Returns are presented gross and net of management fees and include the reinvestment of all income. Net of fee performance was calculated using actual management fees. The annual composite dispersion presented is an asset-weighted standard deviation calculated for the accounts in the composite the entire year. Policies for valuing portfolios, calculating performance, and preparing compliant presentations are available upon request. The investment management fee schedule for the composite prior to 2017 was 1.25% on the first \$5 million and 1.00% after \$5 million, with a minimum of \$15,000.00 annually. As of January 2017, management fee schedule is 1% with a minimum \$50,000 annually. Actual investment advisory fees incurred by clients may vary.